Revolutionizing Renal Cancer Monitoring: A New Approach

A groundbreaking study suggests that a straightforward urine test could offer a highly accurate method for detecting the return of renal cancer, also known as kidney cancer, in post-operative patients. This innovative approach has the potential to considerably reduce the reliance on frequent and frequently enough burdensome computerized tomography (CT) scans [[1]].

The Aur87A Study: An International collaboration

The international research endeavor, dubbed Aur87A, was spearheaded by a team of Swedish researchers. The study encompassed 134 individuals across 23 medical centers spanning the UK, Europe, the USA, and Canada. All participants had received a diagnosis of clear cell renal cell carcinoma (CCRCC), the most prevalent form of kidney cancer [[3]], which was confined to the kidneys and treated surgically.

It’s crucial to note that approximately 20% of patients with this specific type of kidney cancer experience a recurrence, typically within the initial two years following surgery.Current monitoring protocols primarily involve CT scans, with the frequency tailored to each patient’s individual risk profile [[2]].

The Gagome Score: A Novel Biomarker

During the study, participants underwent both standard CT scans and a novel urine test conducted every three months. This urine test analyzed the levels of specific sugar molecules, known as glycosaminoglycans, to generate a risk assessment score, ranging up to 100, termed the Gagome score.

after an 18-month observation period, 15% of the patients experienced cancer recurrence. The study revealed that the urine test demonstrated a remarkable 90% accuracy rate in detecting these recurrences. Moreover, the test successfully ruled out cancer recurrence in slightly over half of the patients who remained cancer-free.

Expert Insights on the Benefits

Associate Professor Saeed Dabestani, from Lund University and a urologist at Kristiastad central Hospital in Sweden, emphasized the meaning of this new test in managing cancer recurrence:

Computerized tomographs frequently enough identify too small lesions to be biopsy, and we do not know if these are signs of cancer recurrence or not. The only option is more frequent monitoring through additional scans, which is unpleasant to patients and often does not bring significant benefits.
Saeed Dabestani, Lund University

If we have a urine test that can look precisely if the disease has returned, we can better evaluate the risk level and reduce the frequency of the necessary tomographs. Based on the results so far, it is indeed likely that the number of scans can be reduced to half without risks.
Saeed Dabestani, Lund University

Future Research Directions

The findings from this study are slated for presentation at the Congress of the European Urology Association (EAU) in Madrid and have been accepted for publication in the esteemed European Urology Oncology journal. Researchers are currently enrolling a second cohort of patients to further validate the Aur87A study, with anticipated results expected later this year.

Kidney Cancer: Understanding the Disease

Kidney cancer, also known as renal cancer, arises when healthy kidney cells undergo uncontrolled growth, leading to the formation of tumors. While early stages frequently enough present without noticeable signs or symptoms [[1]], advanced stages can manifest as flank pain, blood in the urine, and high blood pressure [[2]]. Renal cell carcinoma is the most prevalent type of kidney cancer in adults [[3]], emphasizing the importance of early detection and effective monitoring strategies.